Search

Your search keyword '"Anti-HIV agents -- Prices and rates"' showing total 114 results
Start Over Descriptor "Anti-HIV agents -- Prices and rates"
114 results on '"Anti-HIV agents -- Prices and rates"'

1. Activists renew fight to cover HIV drugs

Author

Alltucker, Ken

Subjects
HIV testing -- Prices and rates, AIDS activists -- Beliefs, opinions and attitudes -- Health aspects -- Insurance, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Sexually transmitted diseases -- Prevention, Company pricing policy, News, opinion and commentary
Abstract

Byline: Ken Alltucker, USA TODAY When Nicklaus Chalk started law school at the University of California, Berkeley, last fall, one of his top priorities was to take care of his [...]

Published
2022

2. Martin Shkreli's former company reaches $40 million settlement in price-gouging case

Author

Bogage, Jacob

Subjects
Turing Pharmaceuticals AG -- Cases, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Price gouging -- Remedies, Compromise and settlement, Pharmaceutical industry -- Cases, Company legal issue, Company pricing policy, General interest, News, opinion and commentary, Daraprim (Medication) -- Prices and rates
Abstract

Byline: Jacob Bogage A pharmaceutical company formerly owned by Martin Shkreli will pay as much as $40 million to resolve price-gouging allegations brought by federal regulators and seven states. Vyera [...]

Published
2021

3. Two PrEP Meds Work Equally Well; One Is Much Cheaper

Subjects
Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Company pricing policy, Health, Descovy (Medication) -- Supply and demand -- Prices and rates -- Statistics, Truvada (Medication) -- Supply and demand -- Statistics -- Prices and rates
Abstract

Byline: Ernie Mundell and Robert Preidt HealthDay Reporters THURSDAY, Aug. 5, 2021 (HealthDay News) -- The two HIV prevention drugs available in the United States are equally safe and effective, [...]

Published
2021

5. An AIDS drug feud

Author

Tremblay, Jean-Francois

Subjects
Cipla Ltd. -- Prices and rates, Cipla Ltd. -- Investigations, Pharmaceutical industry -- Prices and rates, Pharmaceutical industry -- Investigations, Anti-HIV agents -- Prices and rates, Antiviral agents -- Prices and rates, Non-governmental organizations -- Beliefs, opinions and attitudes, Company pricing policy, Company legal issue, Chemicals, plastics and rubber industries, Engineering and manufacturing industries, Viraday (Medication) -- Prices and rates
Abstract

AIDS Healthcare Foundation (AHF) has accused Cipla, an Indian generic drug maker of charging high prices for AIDS drugs in India.

Published
2007

6. Gilead CEO insists federal patent for HIV prevention pill Truvada is invalid

Author

Rowland, Christopher

Subjects
Gilead Sciences Inc. -- Officials and employees -- Intellectual property, Biological products industry -- Officials and employees -- Intellectual property, Chief executive officers -- Beliefs, opinions and attitudes, Anti-HIV agents -- Prices and rates, Death, Capital punishment, Sexually transmitted disease prevention, HIV, Company pricing policy, General interest, News, opinion and commentary, Truvada (Medication) -- Prices and rates
Abstract

Byline: Christopher Rowland WASHINGTON - The CEO of Gilead Sciences, the nation's leading manufacturer of HIV drugs, defended the high cost of a key drug that prevents the potentially lethal [...]

Published
2019

7. 'We all have AIDS': case for reducing the cost of HIV drugs to zero. (Education and Debate)

Author

Berwick, Donald, Sykes, Richard, and Achmat, Zackie

Subjects
Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Marketing -- Prices and rates, Health, Company marketing practices, Company pricing policy, Prices and rates, Marketing
Abstract

An editorial last year in the Washington Post challenged directors of drug companies to reduce the cost of HIV drugs in poor countries to zero. Here the reproduced editorial is [...]

Published
2002

8. Liberals Want to 'Crush' Fake News; Washington Post's Columinist: Trump Swamp Will Deepen; Shkreli's Company Spiked AIDS Drug Price by 5000

Subjects
Turing Pharmaceuticals L.L.C. -- Officials and employees -- Prices and rates, Anti-HIV agents -- Prices and rates, Deception -- Political aspects, Media hoaxes -- Political aspects, President of the United States -- Beliefs, opinions and attitudes -- Political activity, Columnists -- Beliefs, opinions and attitudes, Pharmaceutical industry -- Officials and employees -- Prices and rates, Misinformation -- Political aspects, Company pricing policy, General interest, News, opinion and commentary
Abstract

TUCKER CARLSON, FOX NEWS HOST: A 'Fox News' alert. President-elect Donald Trump is taking his thank you tour to Grand Rapids on the west coast of Michigan tonight. The second [...]

Published
2016

9. South Africa: AIDS ruling

Author

Swarns, Rachel L.

Subjects
HIV infection in pregnancy -- Laws, regulations and rules, HIV patients -- Care and treatment, Drugs -- Prices and rates, Anti-HIV agents -- Prices and rates, South Africa -- Laws, regulations and rules
Published
2002

11. South Africa: AIDS drug trial

Subjects
Doctors Without Borders -- Social policy, Anti-HIV agents -- Prices and rates, South Africa -- Health aspects
Published
2002

13. ARV prices nosedive after Clinton brokering

Author

Sharma, Dinesh C.

Subjects
HIV infection -- Prevention, HIV infection -- Care and treatment, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Marketing, Company pricing policy, Company marketing practices
Published
2003

14. Bloated prices on AIDS drug scrutinized

Author

McCoy, Kevin

Subjects
Turing Pharmaceuticals L.L.C. -- Investigations -- Records and correspondence, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Investigations -- Records and correspondence, Legislative hearings -- Planning, Company legal issue, Company business planning, Company pricing policy, News, opinion and commentary, Daraprim (Medication) -- Prices and rates
Abstract

Byline: Kevin McCoy, @kmccoynyc, USA TODAY Former Turing Pharmaceuticals CEO Martin Shkreli projected more than $200million in annual sales of Daraprim, the prescription drug for which the firm imposed a [...]

Published
2016

15. HIV/AIDS Treatment for Millions

Author

Binswanger, Hans P.

Subjects
Merck & Company Inc. -- Management -- Prices and rates, GSK PLC -- Management -- Prices and rates, Bristol-Myers Squibb Co. -- Management -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Drugs -- Prices and rates, AIDS (Disease) -- Drug therapy, Pharmaceutical industry -- Prices and rates, Company business management, Company pricing policy, Science and technology
Abstract

Treatment of HIV/AIDS involves treatment of opportunistic infections, prophylaxis, and antiretroviral (ARV) therapy. ARV therapy suppresses the virus and enables patients to live for many years. Three or more ARV [...]

Published
2001

16. Medicines for all, not just the rich

Author

Davey, Sheila

Subjects
Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Finance
Abstract

March brought bad news for the HIV virus, but good news for HIV/AIDS patients, particularly those in poor countries. In the second week of the month, Merck and Co., a [...]

Published
2001

17. Indian company offers low cost AIDS drugs

Author

Kumar, Sanjay

Subjects
Doctors Without Borders -- Services, Anti-HIV agents -- Prices and rates, India -- Health aspects, Cipla Ltd. -- Prices and rates
Published
2001

18. Companies reduce prices for HIV drugs in developing countries

Author

Gottlieb, Scott

Subjects
Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Prices and rates, AIDS (Disease) -- Drug therapy
Abstract

In an unprecedented effort to combat acquired immunodeficiency syndrome (AIDS) in sub-Saharan Africa, five of the world's leading pharmaceutical companies have agreed to decrease the price of drugs used to [...]

Published
2000

20. Cautious welcome for antiretroviral cost reduction in South Africa

Author

Baleta, Adele

Subjects
Anti-HIV agents -- Prices and rates, South Africa -- Health aspects, Glaxo Wellcome PLC -- Prices and rates, Boehringer Ingelheim GmbH -- Prices and rates, Bristol-Myers Squibb Co. -- Prices and rates, Roche Holding Ltd. -- Prices and rates, Merck & Company Inc. -- Prices and rates
Published
2000

22. Medicine as a Public Good

Author

Gebbie, Kristine M.

Subjects
AIDS (Disease) -- Drug therapy, Anti-HIV agents -- Analysis, Anti-HIV agents -- Prices and rates, Antiviral agents -- Analysis, Antiviral agents -- Prices and rates, Medical policy -- Laws, regulations and rules, Company pricing policy, Government regulation, Health, Ryan White Care Act
Abstract

[AIDS Reader. 2006;16:235, 238] Key words: HIV/AIDS - ADAP - Ryan White Care Act - Health care policy - Medications As this column is being written, the Kaiser Family Foundation [...]

Published
2006

23. Approval of novel anti-HIV drug offers patients hope. (Rx Care)

Author

LoBuono, Charlotte

Subjects
Company pricing policy, Chronimed Inc. -- Distribution, Chronimed Inc. -- Contracts, Roche Holding AG -- Product development, Roche Holding AG -- Distribution, Roche Holding AG -- Contracts, Roche Holding AG -- Prices and rates, Trimeris Inc. -- Product development, Trimeris Inc. -- Distribution, Trimeris Inc. -- Contracts, Trimeris Inc. -- Prices and rates, Fuzeon (Medication) -- Adverse and side effects, Fuzeon (Medication) -- Distribution, Fuzeon (Medication) -- Contracts, Fuzeon (Medication) -- Prices and rates, Fuzeon (Medication) -- Dosage and administration, Fuzeon (Medication) -- Licensing agreements, Anti-HIV agents -- Licensing agreements, Anti-HIV agents -- Dosage and administration, Anti-HIV agents -- Distribution, Anti-HIV agents -- Contracts, Anti-HIV agents -- Prices and rates, Anti-HIV agents -- Adverse and side effects, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Distribution, Pharmaceutical industry -- Contracts, Pharmaceutical industry -- Prices and rates, Antiviral agents -- Licensing agreements, Antiviral agents -- Contracts, Antiviral agents -- Dosage and administration, Antiviral agents -- Distribution, Antiviral agents -- Prices and rates, Antiviral agents -- Adverse and side effects
Abstract

Healthcare providers can now treat HIV-infected patients with an antiretroviral drug unlike any other. The Food & Drug Administration recently granted accelerated approval of enfuvirtide (Fuzeon, Roche/Trimeris) for use in [...]

Published
2003

24. YUSUF HAMIED

Subjects
Cipla Ltd. -- Management, Pharmaceutical industry -- Management, Anti-HIV agents -- Prices and rates
Published
2001

25. Glaxo cuts drug prices for developing countries

Author

Wise, Jacqui

Subjects
GSK PLC -- Prices and rates, Antimalarials -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Health, Company pricing policy, Prices and rates
Abstract

The pharmaceutical company GlaxoSmithKline is to lower the cost to the developing world of its antimalarial and newer HIV and AIDS drugs--a move welcomed by the World Health Organization (WHO) [...]

Published
2001

26. NO EASY CURE

Author

STOKES, BRUCE

Subjects
AIDS (Disease) -- Drug therapy, Drugs -- Prices and rates, Anti-HIV agents -- Prices and rates, Developing countries -- Health aspects, Pharmaceutical industry -- International aspects
Abstract

AIDS activists' allegations that price-gouging pharmaceutical companies are essentially practicing genocide against Third World victims of the disease--and the drug firms' response, the dramatic slashing of prices for AIDS drugs […]

Published
2001

27. Drug company to sell AIDS drugs at less than cost price

Author

Gottlieb, Scott

Subjects
Bristol-Myers Co. -- Marketing -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Health, Company marketing practices, Company pricing policy, Prices and rates, Marketing
Abstract

Bristol-Myers Squibb has raised the stakes in an effort to cut the prices of drugs to treat AIDS in Africa by announcing that it will sell two antiretroviral drugs in [...]

Published
2001

28. Paying for AIDS

Author

Power, Carla, Masland, Tom, Pan, Esther, Santoro, Lara, Moreau, Ron, and Margolis, Mac

Subjects
South Africa -- Diseases, Merck & Company Inc. -- Prices and rates, Cipla Ltd. -- Prices and rates, GSK PLC -- Prices and rates, Hetero International -- Prices and rates, Generic drugs -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Drugs -- Prices and rates, Developing countries -- Diseases, Pharmaceutical industry -- Prices and rates, Company pricing policy, General interest, News, opinion and commentary
Abstract

On Jan. 11, just after London-based GlaxoSmithKline became the world's largest drug company, its new CEO, Jean-Pierre Garnier, spoke to the company's 100,000 employees via satellite. There was the predictable [...]

Published
2001

30. Global News Roundup

Subjects
West Nile fever -- Prevention, Medical research -- Finance, Medicine, Experimental -- Finance, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Malaria -- Prevention, Health, Company financing, Company pricing policy, Finance, Prevention, Prices and rates
Abstract

African heads of state promise action against malaria More than 50 African heads of state have pledged to halve the continent's malaria deaths by 2010. The declaration was made at [...]

Published
2000

31. AIDS: A Price Break for Antiretroviral Drugs In 70 of the World's Poorest Countries

Author

Mcneil, Donald G., Jr.

Subjects
Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Highly active antiretroviral therapy -- Prices and rates, AIDS treatment -- Prices and rates, Company pricing policy, General interest, News, opinion and commentary
Abstract

In a development that could improve AIDS treatment worldwide, modern antiretroviral drugs will be sold at lower prices in 70 of the world's poorest countries. The most important price breaks, [...]

Published
2011

32. Glaxo cuts price of HIV drugs for world's poorest countries

Subjects
GlaxoSmithKline PLC -- Public relations, GlaxoSmithKline PLC -- International marketing, Pharmaceutical industry -- Public relations, Pharmaceutical industry -- International marketing, Corporate social responsibility -- Economic aspects, Anti-HIV agents -- International marketing, Anti-HIV agents -- Prices and rates, Antiviral agents -- International marketing, Antiviral agents -- Prices and rates, Company public relations, Company pricing policy, Banking, finance and accounting industries, Business, Business, international
Abstract

UK pharmaceutical firm GlaxoSmithKline PLC reduced prices on its anti-HIV agents to developing nations, the company's fifth such discount since 1997. The across-the-board discount for these therapeutics averages 21%, with the largest discount on Ziagen, at nearly 40%.

Published
2008

33. Boehringer Ingelheim. (Panorama: Central America)

Author

Diaz, Oscar

Subjects
Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Prices and rates -- Alliances and partnerships, Company pricing policy, Merck & Company Inc. -- Prices and rates -- Alliances and partnerships, GSK PLC -- Prices and rates -- Alliances and partnerships, Bristol-Myers Squibb Co. -- Prices and rates -- Alliances and partnerships, Boehringer Ingelheim GmbH -- Prices and rates -- Alliances and partnerships, Roche Holding AG -- Prices and rates -- Alliances and partnerships
Abstract

BOEHRINGER INGELHEIM, a German pharmaceutical company, Switzerland's Roche, the United Kingdom's GlaxoSmithKline, the United States' Bristol Myers Squibb and Merck signed an agreement to reduce by 50% the price of [...]

Published
2003

34. Brazil Near Deal With Abbott For Price Cut on AIDS Drug

Author

Prada, Paulo

Subjects
Company pricing policy, Abbott Laboratories (Abbott Park, Illinois) -- Prices and rates, Kaletra (Medication) -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Prices and rates, Brazil -- Health policy
Abstract

Brazil said on Tuesday that it was close to completing an agreement with Abbott Laboratories that would almost halve the price it pays for Kaletra, a drug used to treat […]

Published
2005

35. National Briefing Washington: U.S. Refuses To Intervene On AIDS Drug Price

Subjects
Company pricing policy, Abbott Laboratories (Abbott Park, Illinois) -- Prices and rates, Norvir (Medication) -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Price gouging, Pharmaceutical industry -- Prices and rates
Abstract

The government refused to intervene against a rapid price increase for an AIDS drug, Norvir, deciding not to override patents on the treatment in an effort to force a lower […]

Published
2004

36. Medical dilemma: costly new drug for AIDS means some go without; programs for the uninsured are facing tough choices with advent of Fuzeon; a tale of two patients

Author

Fuhrmans, Vanessa

Subjects
Anti-HIV agents -- Finance, Anti-HIV agents -- Prices and rates, Antiviral agents -- Finance, Antiviral agents -- Prices and rates, Discrimination in medical care -- Economic aspects, Discrimination in medical care -- Ethical aspects, Discrimination in medical care -- Social aspects, Drug therapy -- Finance, Drug therapy -- Services, HIV patients -- Care and treatment, HIV patients -- Drug therapy, HIV patients -- Personal narratives, HIV patients -- Services, HIV patients -- Social aspects, Medically uninsured persons -- Care and treatment, Medically uninsured persons -- Drug therapy, Medically uninsured persons -- Personal narratives, Medically uninsured persons -- Services, Medically uninsured persons -- Social aspects, State government -- Finance, State government -- Services, Company financing, Company pricing policy, State/local government software, Business, Business, general, Fuzeon (Medication) -- Finance, Fuzeon (Medication) -- Prices and rates
Published
2004

37. Clinton Group Gets Discount For AIDS Drugs

Author

Altman, Lawrence K.

Subjects
Company pricing policy, Bill, Hillary & Chelsea Clinton Foundation -- Social policy -- Economic policy, Generic drugs -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Economic policy -- Social policy -- Prices and rates
Abstract

Former President Bill Clinton announced yesterday that his foundation had brokered an agreement with four generic drug companies to cut the cost of certain AIDS antiretroviral drugs by about a […]

Published
2003

38. Steep price of Roche AIDS drug may put it out of patients' reach

Author

Fuhrmans, Vanessa

Subjects
Roche Holding AG -- Prices and rates, Pharmaceutical industry -- Prices and rates, Anti-HIV agents -- Prices and rates, Pricing -- Ethical aspects, Antiviral agents, Product price, Company pricing policy, Business, Business, general, Fuzeon (Medication) -- Prices and rates
Published
2003

39. Funding woes slow effort

Author

Schoofs, Mark and Zimmerman, Rachel

Subjects
Barcelona, Spain (City) -- Conferences, meetings and seminars, AIDS (Disease) -- Conferences, meetings and seminars, International economic relations -- Conferences, meetings and seminars, Epidemics -- International aspects, HIV patients -- Statistics, Developing countries -- Health aspects, Economic assistance -- International aspects, Anti-HIV agents -- Prices and rates, Business, Business, general
Published
2002

41. World AIDS experts debate treatment vs. prevention

Author

Zimmerman, Rachel and Schoofs, Mark

Subjects
World AIDS Conference -- 2002 AD, AIDS patients -- Care and treatment, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Prices and rates, AIDS (Disease) -- Prevention, Developing countries -- Finance, Business, Business, general
Published
2002

42. Thai drug is the next front in patent battle

Author

Zimmerman, Rachel and Frank, Robert, Swiss photographer

Subjects
Thailand -- Health aspects, Anti-HIV agents -- Prices and rates, Drug therapy, Combination -- Economic aspects, Pharmaceutical policy -- Thailand, AIDS patients -- Care and treatment, AIDS (Disease) -- Drug therapy, Pharmaceutical industry -- Prices and rates, Business, Business, general
Published
2002

43. Enlisting multinationals in battle

Author

Schoofs, Mark

Subjects
AIDS patients -- Care and treatment, International business enterprises -- Human resource management, Workers -- Health aspects, Pharmaceutical industry -- Prices and rates, Anti-HIV agents -- Prices and rates, Business, Business, general
Published
2001

45. Brazil official cites U.S. stance on Cipro

Subjects
Pharmaceutical industry -- Licensing agreements, Anti-HIV agents -- Prices and rates, Antibiotics -- Prices and rates, Hypocrisy -- Criticism and interpretation, Business, Business, general, Cipro (Medication) -- Prices and rates
Published
2001

46. Boehringer, Axios begin to distribute no-cost AIDS drug

Author

Waldholz, Michael

Subjects
Africa -- Diseases, Boehringer Ingelheim GmbH -- Distribution, Axion Pharmaceuticals Inc. -- Distribution, Pharmaceutical industry -- Distribution, Anti-HIV agents -- Prices and rates, AIDS patients -- Care and treatment, Business, Business, general, Viramune (Medication) -- Distribution
Published
2001

47. U.N. AIDS conference avoids the real issues

Author

Ayittey, George B.N.

Subjects
Africa -- Health aspects, AIDS (Disease) -- Conferences, meetings and seminars, Anti-HIV agents -- Prices and rates, Pharmaceutical industry -- Prices and rates, Military policy -- Africa, Public health -- Africa, Business, Business, general, United Nations -- Conferences, meetings and seminars
Published
2001

48. Kenya moves on cheaper AIDS drugs

Subjects
Kenya -- Laws, regulations and rules, Generic drugs -- Prices and rates, Pharmaceutical industry -- Product information, Anti-HIV agents -- Prices and rates, AIDS (Disease) -- Drug therapy, Business, Business, general
Published
2001

49. Lifting the curtain on the real costs of making AIDS drugs

Author

Petersen, Melody

Subjects
Company pricing policy, Bristol-Myers Squibb Co. -- Prices and rates, Cipla Ltd. -- Prices and rates, Boehringer Ingelheim GmbH -- Prices and rates, GlaxoSmithKline PLC -- Prices and rates, Merck & Company Inc. -- Prices and rates, Sustiva (Medication) -- Prices and rates, Crixivan (Medication) -- Prices and rates, Combivir (Medication) -- Prices and rates, Zerit (Medication) -- Prices and rates, Videx (Medication) -- Prices and rates, Retrovir (Medication) -- Prices and rates, Epivir (Medication) -- Prices and rates, Viramune (Medication) -- Prices and rates, Generic drugs -- Prices and rates, Antiviral agents -- Prices and rates, Anti-HIV agents -- Prices and rates, Drugs -- Prices and rates, Anti-infective agents -- Prices and rates, Pharmaceutical industry -- Prices and rates
Abstract

About a dozen foreign drug manufacturers, working in the shadows to make copycat versions of patented AIDS medicines, are shedding new light on how little these medicines cost to make. […]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results